Yet another major pharmaceutical manufacturer has agreed to implement President Donald Trump’s “most favored nation” drug pricing plan and to make its products available on a website for direct-to-consumer sales that will be branded with the president’s name.
AstraZeneca, the U.K.-based drug company, is joining its New York-based rival Pfizer in a White House-led initiative to adopt the president’s preferred pricing model. The company’s CEO, Pascal Soriot, announced the move alongside Trump in the Oval Office on Friday.
